Home | Sitemap | Contact BRP

Search this site

Dr. Hari Sankaran

Medical Officer, Division of Cancer Treatment and Diagnosis

Biosketch

Dr. Sankaran has been a with the National Cancer Institute since 2019 and was appointed as a medical officer in 2020. He did his residency in Pediatrics in 2012 and fellowship in Pediatric Hematology-Oncology in 2015 at Baylor College of Medicine. During his fellowship, Dr. Sankaran also completed a Masters in Epidemiology at the University of Texas School of Public Health in 2016. Pursuing his passion in global health with a pediatric oncology focus, Dr. Sankaran moved to India in 2016-2019 to work at 2 prestigious oncology institutions in Cochin and Mumbai. His research interests include evaluating biomarkers in clinical trials, study design, survival analysis, and global health. Dr. Sankaran serves on the Core Correlative Science Committee and attends on the Pediatric Oncology Branch service in the Clinical Care Center. Dr. Sankaran also sits on the editorial board of the NCI PDQ Cancer Integrative, Alternative, and Complementary Therapies Editorial Board.

Research Interests

Evaluating biomarkers in clinical trials, study design, survival analysis, and global health

Selected Recent Publications:

Sankaran, H., H. E. Danysh, M. E. Scheurer, M. F. Okcu, S. X. Skapek, D. S. Hawkins, L. G. Spector, E. B. Erhardt, S. Grufferman and P. J. Lupo (2016). "The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group." Pediatr Blood Cancer 63(9): 1557-1562.

Sankaran, H., S. Sengupta, V. Purohit, A. Kotagere, N. R. Moulik, M. Prasad, C. Dhamne, G. Narula, S. Banavali and V. Gota (2020). "A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia." Br J Clin Pharmacol 86(6): 1081-1088.

O'Sullivan Coyne G, Naqash AR, Sankaran H, Chen AP. Advances in the management of alveolar soft part sarcoma. Curr Probl Cancer. 2021 Aug;45(4):100775. doi: 10.1016/j.currproblcancer.2021.100775.

J. Krushkal, S. Negi, L. Yee, J. Evans, T. Grkovic, A. Palmisano, J. Fang, H. Sankaran, L.M. McShane, Y. Zhao, B. O'Keefe. Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products. Molecular Oncology 15:381-406, 2021

Sankaran, H., Finnigan, S.R., McShane, L.M., Best, A.F. and Seibel, N.L. (2022), Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network. Cancer.

Sankaran, H., Negi, S., McShane, L.M. et al. Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products. BMC Cancer 22, 512 (2022).

Schroeder BA, Jess J, Sankaran H, Shah NN. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. Curr Opin Hematol. 2022 Jul 1;29(4):225-232.